Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

被引：0
|
作者：
Ahn, Eugene R.
Mangat, Pam K.
Garrett-Mayer, Elizabeth
Halabi, Susan
Dib, Elie G.
Haggstrom, Daniel Ernest
Alguire, Kathryn B.
Alvarez, Ricardo H.
Calfa, Carmen Julia
Cannon, Timothy Lewis
Crilley, Pamela A.
Gaba, Anu G.
Marr, Alissa S.
Sangal, Ashish
Thota, Ramya
Antonelli, Kaitlyn R.
Islam, Samiha
Rygiel, Andrew Lawrence
Bruinooge, Suanna S.
Schilsky, Richard L.
机构：
[1] Canc Treatment Ctr Amer, Zion, IL USA
[2] Amer Soc Clin Oncol, Alexandria, VA USA
[3] Med Univ South Carolina, Charleston, SC 29425 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Sanford Hlth, Sioux Falls, SD USA
[6] Levine Canc Inst, Charlotte, NC USA
[7] Grand Rapids Oncol Program, Grand Rapids, MI USA
[8] Canc Treatment Ctr Amer, Newnan, GA USA
[9] Mem Canc Inst, Hollywood, FL USA
[10] Inova Schar Canc Inst, Fairfax, VA USA
[11] Canc Treatment Ctr Amer, Boca Raton, FL USA
[12] Roger Maris Canc Ctr, Fargo, ND USA
[13] Univ Nebraska Med Ctr, Omaha, NE USA
[14] Canc Treatment Ctr Amer, Goodyear, AZ USA
[15] Intermt Healthcare, Murray, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9041
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Ahnert, Jordi Rodon
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Cannon, Timothy Lewis
    Hobbs, Evthokia
    Kalemkerian, Gregory Peter
    Hinshaw, Dominique C.
    Gregory, Abby
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with FGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Calfa, Carmen
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Ahn, Eugene
    Gogineni, Keerthi
    Rohatgi, Nitin
    Burness, Monika L.
    Gaba, Anu
    Hamid, Omid
    Albaghdadi, Tareq
    Conlin, Alison
    Gold, Philip
    Rodon, Jordi
    Thota, Ramya
    Schilsky, Richard L.
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Wentzel, Kristopher
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Ding, Li
    Pisick, Evan
    Krishnan, Mridula
    Behl, Deepti
    Alese, Olatunji B.
    Calfa, Carmen J.
    Cooper, Kathrine A.
    Duvivier, Herbert L.
    Induru, Raghava Reddy
    Ruzich, Janet C.
    Zhao, Song
    Grantham, Gina N.
    Gregory, Abigail
    Halabi, Susan
    Schilsky, Richard L.
    CANCER RESEARCH, 2023, 83 (08)
  • [24] Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Calfa, Carmen Julia
    Rothe, Michael
    Srkalovic, Gordan
    Duvivier, Herbert Leon
    Behl, Deepti
    Straughn, J. Michael
    Yost, Kathleen J.
    Mehmi, Inderjit
    Pisick, Evan P.
    Sharma, Bhavina B.
    Thota, Ramya
    Veljovich, Dan Steven
    Alese, Olatunji B.
    Cannon, Timothy Lewis
    Gaba, Anu G.
    Urba, Walter John
    von Mehren, Margaret
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
    Yost, Kathleen J.
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Duvivier, Herbert Leon
    Ahn, Eugene R.
    Chiu, Vi Kien
    Khalil, Maged F.
    Kim, Brian
    Prinz, Allison Marie
    Grantham, Gina N.
    Gregory, Abby
    Hinshaw, Dominique C.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 106 - 106
  • [26] Pertuzumab plus trastuzumab (P plus T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
    Ganti, A. K.
    Rothe, M.
    Mangat, P. K.
    Garrett-Mayer, E.
    Dib, E. G.
    Duvivier, H.
    Ahn, E.
    Behl, D.
    Borghaei, H.
    Balmanoukian, A. S.
    Gaba, A.
    Li, R.
    Osei-Boateng, K.
    Thota, R.
    O'Lone, R.
    Grantham, G. N.
    Halabi, S.
    Schilsky, R. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S997 - S998
  • [27] Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
    Grem, Jean L.
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Khalil, Maged F.
    Rogosin, Shane O.
    Salmon, John Stuart
    Cannon, Timothy Lewis
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [28] Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Klute, Kelsey A.
    Rothe, Michael
    Garrett-Mayer, Elizabeth
    Mangat, Pam K.
    Nazemzadeh, Reza
    Yost, Kathleen J.
    Duvivier, Herbert L.
    Ahn, Eugene R.
    Cannon, Timothy L.
    Alese, Olatunji B.
    Krauss, John C.
    Thota, Ramya
    Calfa, Carmen J.
    Denlinger, Crystal S.
    O'Lone, Raegan
    Halabi, Susan
    Grantham, Gina N.
    Schilsky, Richard L.
    JCO PRECISION ONCOLOGY, 2022, 6
  • [29] Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study
    Ahn, E.
    Rothe, M.
    Mangat, P. K.
    Garrett-Mayer, E.
    Al Baghdadi, T.
    Baron, A. D.
    Krauss, J. C.
    Balmanoukian, A. S.
    Bauman, J. R.
    Hameed, M. K.
    Mileham, K. F.
    Thota, R.
    Gold, P. J.
    Meric-Bernstam, F.
    Powell, S. F.
    Yang, E. S.
    O'Lone, R.
    Grantham, G. N.
    Halabi, S.
    Schilsky, R. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S583 - S584
  • [30] Nivolumab plus ipilimumab (N plus I) in patients (pts) with pancreatic cancer (PC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Hosein, Peter Joel
    Rothe, Michael
    Garrett-Mayer, Elizabeth
    Baron, Ari David
    Cannon, Timothy Lewis
    Pisick, Evan P.
    Hobbs, Evthokia
    Mileham, Kathryn Finch
    Tinguely, Matthew Joseph
    Frimer, Marina
    Gold, Philip Jordan
    Klute, Kelsey
    Rogers, Sherise C.
    Sahai, Vaibhav
    Sohal, Davendra
    Thomas, Sachdev P.
    Winegarden, Jerome Dallas
    Gregory, Abby
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 715 - 715
12345